Literature DB >> 24078689

Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.

Gaëlle David1, Zakia Djaoud, Catherine Willem, Nolwenn Legrand, Pauline Rettman, Katia Gagne, Anne Cesbron, Christelle Retière.   

Abstract

The interactions of killer Ig-like receptor 2D (KIR2D) with HLA-C ligands contribute to functional NK cell education and regulate NK cell functions. Although simple alloreactive rules have been established for inhibitory KIR2DL, those governing activating KIR2DS function are still undefined, and those governing the formation of the KIR2D repertoire are still debated. In this study, we investigated the specificity of KIR2DL1/2/3 and KIR2DS1/2, dissected each KIR2D function, and assessed the impact of revisited specificities on the KIR2D NK cell repertoire formation from a large cohort of 159 KIR and HLA genotyped individuals. We report that KIR2DL2(+) and KIR2DL3(+) NK cells reacted similarly against HLA-C(+) target cells, irrespective of C1 or C2 allele expression. In contrast, KIR2DL1(+) NK cells specifically reacted against C2 alleles, suggesting a larger spectrum of HLA-C recognition by KIR2DL2 and KIR2DL3 than KIR2DL1. KIR2DS2(+) KIR2DL2(-) NK cell clones were C1-reactive irrespective of their HLA-C environment. However, when KIR2DS2 and KIR2DL2 were coexpressed, NK cell inhibition via KIR2DL2 overrode NK cell activation via KIR2DS2. In contrast, KIR2DL1 and KIR2DS2 had an additive enhancing effect on NK cell responses against C1C1 target cells. KIR2DL2/3/S2 NK cells predominated within the KIR repertoire in KIR2DL2/S2(+) individuals. In contrast, the KIR2DL1/S1 NK cell compartment is dominant in C2C2 KIR2DL2/S2(-) individuals. Moreover, our results suggest that together with KIR2DL2, activating KIR2DS1 and KIR2DS2 expression limits KIR2DL1 acquisition on NK cells. Altogether, our results suggest that the NK cell repertoire is remolded by the activating and inhibitory KIR2D and their cognate ligands.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078689     DOI: 10.4049/jimmunol.1301580

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

2.  Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Authors:  P Rettman; F Malard; N Legrand; O Avinens; J-F Eliaou; C Picard; A Dormoy; X Lafarge; M de Matteis; A Kennel; P Loiseau; A Devys; A Boudifa; L Absi; M Fort; D Masson; F Quainon; I Theodorou; A Batho; A Parissiadis; F Delbos; M Drouet; D Senitzer; E Marry; N Raus; I Yakoub-Agha; A Cesbron; C Retière; K Gagne
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

3.  Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Authors:  Gretchen A Hoff; Johannes C Fischer; Katharine Hsu; Sarah Cooley; Jeffrey S Miller; Tao Wang; Michael Haagenson; Stephen Spellman; Stephanie J Lee; Markus Uhrberg; Jeffrey M Venstrom; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-13       Impact factor: 5.742

4.  Partial break in tolerance of NKG2A-/LIR-1- single KIR+ NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation.

Authors:  S Rathmann; C Keck; C Kreutz; N Weit; M Müller; J Timmer; S Glatzel; M Follo; M Malkovsky; M Werner; R Handgretinger; J Finke; P Fisch
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

Review 5.  Future directions of clinical laboratory evaluation of pregnancy.

Authors:  Kenneth D Beaman; Mukesh K Jaiswal; Svetlana Dambaeva; Alice Gilman-Sachs
Journal:  Cell Mol Immunol       Date:  2014-07-21       Impact factor: 11.530

6.  The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.

Authors:  Zahra Kiani; Franck P Dupuy; Julie Bruneau; Bertrand Lebouché; Christelle Retière; Daniel E Geraghty; Nicole F Bernard
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

7.  Pseudomonas aeruginosa Infection Impairs NKG2D-Dependent NK Cell Cytotoxicity through Regulatory T-Cell Activation.

Authors:  Mickael Vourc'h; Gaelle David; Benjamin Gaborit; Alexis Broquet; Cedric Jacqueline; Tanguy Chaumette; Jocelyne Caillon; Antoine Roquilly; Christelle Retiere; Karim Asehnoune
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

Review 8.  NK cell therapy for hematologic malignancies.

Authors:  Rohtesh S Mehta; Brion Randolph; May Daher; Katayoun Rezvani
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

Review 9.  Natural killer cell education in human health and disease.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

10.  A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia.

Authors:  Annettee Nakimuli; Olympe Chazara; Susan E Hiby; Lydia Farrell; Stephen Tukwasibwe; Jyothi Jayaraman; James A Traherne; John Trowsdale; Francesco Colucci; Emma Lougee; Robert W Vaughan; Alison M Elliott; Josaphat Byamugisha; Pontiano Kaleebu; Florence Mirembe; Neda Nemat-Gorgani; Peter Parham; Paul J Norman; Ashley Moffett
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.